Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1 Infected Adults, Adolescents and Children Aged 3 Years and Above

Trial Profile

Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1 Infected Adults, Adolescents and Children Aged 3 Years and Above

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Darunavir (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Janssen R&D Ireland; Janssen Sciences Ireland UC
  • Most Recent Events

    • 20 Sep 2017 Planned number of patients changed from 170 to 133.
    • 20 Sep 2017 Planned number of patients changed from 170 to 133.
    • 20 Sep 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top